^
    1year
    The discovery and preclinical characterization of the potent covalent KRASG12C inhibitor UCT-001024 (AACR 2023)
    UCT-001024 also demonstrates improved plasma and whole brain unbound clearance, and in vivo potency in ectopic xenograft models and a brain-tropic NSCLC metastasis model relative to adagrasib. Additionally, UCT-001024 shows a favorable DDI profile and ion channel safety in an in vitro iPSC-derived cardiomyocyte cardiac proarrhythmia assay.
    Preclinical
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    Krazati (adagrasib) • UCT-001024